Trending Market News

House China committee Chairman John Moolenaar is urging the Federal Reserve to review Hong Kong's access to the FIMA repo facility, a dollar liquidity mechanism for foreign monetary authorities established during COVID-19. The request reflects concerns over China's growing control of Hong Kong and Beijing's efforts to promote the renminbi as a global reserve currency alternative to the U.S. dollar.

• Hong Kong has barely used the FIMA facility since drawing up to $1.4 billion in May 2020, making the immediate financial impact of any restriction relatively small
• China's renminbi currently represents only 2.1% of global reserve holdings compared to the dollar's 56.7%, but Beijing launched its own version of FIMA in June with Hong Kong as its first user
• Economists warn that restricting Hong Kong's access could backfire by reducing mechanisms that reinforce demand for dollars and U.S. Treasurys, potentially undermining rather than bolstering dollar dominance

French banking group BPCE has acquired approximately 7% of Spanish lender Sabadell through market purchases and financial instruments, valued at around €1.19 billion ($1.33 billion). BPCE plans to become a long-term shareholder and will seek board representation while exploring potential cooperation opportunities between the two banks.

• The 7% stake in Sabadell is valued at approximately €1.19 billion at current market prices
• BPCE intends to seek representation on Sabadell's board as part of its long-term shareholder strategy
• The acquisition was made through a combination of market purchases and financial instruments, with both companies exploring future cooperation

President Trump announced that Becton Dickinson, a U.S. medical technology company, has agreed to invest $3 billion to expand domestic manufacturing of essential medical products. More than $1 billion of this investment will go to Nebraska for production of items including needles made with American steel. The company has not yet publicly confirmed the announcement.

• $3 billion total investment commitment to bring medical product manufacturing to the United States
• Over $1 billion specifically allocated to Nebraska facilities for production including needles made with American steel
• Becton Dickinson had not responded to Reuters' request for comment at time of publication

Gulf oil exports excluding Iran recovered to 81% of pre-war levels in September, driven by a 4.2 million barrel-per-day surge in Saudi shipments, according to shipping data. Iranian exports fell to zero due to a US blockade, while other Gulf producers adapted to infrastructure attacks and shipping threats by using 'dark transits' to evade detection. The regional disruptions have worsened global diesel and jet fuel shortages, contributing to near-record fuel prices.

• Combined Gulf flows (excluding Iran) reached 19.2 million bpd in September versus 23.6 million bpd pre-war, with crude recovering to 91% of prior levels while refined fuel exports remain at just 60%
• Saudi Arabia's exports jumped 4.2 million bpd from August to 6.6 million bpd in September, offsetting declines from Kuwait, Qatar, and the total loss of Iranian exports
• Reduced Middle Eastern fuel exports have intensified global diesel and jet fuel shortages, pushing prices to record or near-record levels in multiple markets

The FBI removed an Accenture contractor on Monday following a significant data breach that exposed sensitive personal information of thousands of FBI employees. The incident raises concerns about third-party vendor security risks in government operations.

• An Accenture contractor was directly responsible for the breach that compromised personal details of thousands of FBI personnel
• The FBI took immediate action by removing the contractor from their systems following the security incident
• The breach highlights vulnerabilities in government agencies' reliance on external contractors for sensitive operations

Pinterest announced the appointment of James Dibbo, a 56-year-old Amazon executive, as its new Chief Financial Officer effective October 26. Dibbo, who has led finance for Amazon's Ads, Prime Video, and MGM Studios businesses, will replace Julia Donnelly who is leaving to join an early-stage private company. The leadership change comes as Pinterest faces slower growth amid intense competition in digital advertising from larger players like Meta.

• Dibbo brings experience leading finance for major Amazon divisions including Ads, Prime Video, and Amazon MGM Studios, with expertise in consumer experience, shopping, advertising, and technology at scale
• Outgoing CFO Julia Donnelly, who joined Pinterest in 2023, will depart October 30 to pursue an opportunity at a private, early-stage company
• Pinterest has recently forecast slower growth as it competes in a digital advertising market dominated by larger players such as Meta

L'Oreal has hired restructuring advisers to address mounting U.S. legal liabilities related to talc and other chemical ingredients used in some of its cosmetic products. The company's U.S. subsidiary is working with legal and financial advisers to manage mass lawsuits from individuals claiming the talc products caused illness.

• L'Oreal US is working with restructuring counsel Weil Gotshal & Manges and investment bank Ducera Partners to explore options for handling the liabilities
• The company faces mass lawsuits from individuals alleging that talc products have caused illness
• Reuters could not independently verify the Wall Street Journal report on the advisory engagements

Ariel Investments, holding a 5.4% stake in Mattel, is pressuring the toymaker to explore strategic alternatives including a potential sale, according to a Wall Street Journal report. The activist investor believes Mattel's current market valuation does not reflect its true worth. Mattel's board responded by stating they remain committed to acting in the best interests of all shareholders.

• Ariel Investments owns a 5.4% stake in the Barbie maker and is advocating for strategic alternatives including a possible sale
• The investor firm believes Mattel's stock is undervalued relative to the company's actual worth
• Mattel's management has defended its current strategy, emphasizing the board's commitment to shareholder interests

Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at over $5 billion including debt, according to the Financial Times. The deal could be announced as soon as Tuesday but talks could still fall apart. The acquisition would expand McKesson's healthcare services footprint beyond physician offices into home and alternate-site care settings.

• Option Care provides infusion services allowing patients to receive intravenous medications at home or outpatient settings rather than in hospitals
• McKesson's oncology & multispecialty segment revenue rose 33% in the latest quarter, driven by specialty distribution growth and acquisitions
• An analyst noted the 'strategic rationale' makes sense as it would extend McKesson's reach into home and alternate-site care settings

Genmab and AbbVie announced that their combination treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) reduced the risk of disease progression or death by 51% compared to standard treatment in a late-stage study. The therapy combines epcoritamab, an immune-based therapy, with R-CHOP, the current standard treatment for DLBCL, the most common form of blood cancer affecting lymph cells.

• The combination reduced disease progression or death risk by 51% compared to R-CHOP alone in newly diagnosed DLBCL patients
• This is the first late-stage study of a bispecific antibody combination to significantly improve progression-free survival in first-line DLBCL treatment
• Epcoritamab is not yet approved for newly diagnosed patients and has only been tested in those who have not received prior treatment

Boeing secured a seven-year contract worth up to $14.7 billion from Lockheed Martin to produce PAC-3 MSE seekers, the guidance components for Patriot air defense missiles. The deal enables Boeing to triple production capacity as demand surges due to conflicts in Iran and Ukraine straining U.S. weapons stockpiles.

• The contract allows Boeing to triple production of PAC-3 MSE seekers, which detect and track targets for the Patriot missile defense system's hit-to-kill interceptors
• Lockheed Martin previously announced plans to increase PAC-3 missile production capacity from 600 to 2,000 units annually, with a separate U.S. Army contract worth up to $58.6 billion
• Industry executives warn that Congress has not yet appropriated funding for these deals, potentially preventing contractors from investing at scale in components and facilities

Starbucks' recovery plan under CEO Brian Niccol is showing progress with improved in-store experiences, though high valuations are limiting stock gains. The company trades at 30 times forward earnings versus an industry average of 12x EV/EBITDA, but recent divestiture of 60% of China retail operations has strengthened financial flexibility for potential buybacks and dividends.

• Starbucks has grown from 700 stores in the mid-1990s to 41,000 today, but mobile ordering rushed the experience and quality declined before new CEO Niccol began recovery efforts
• Stock trades at 30x forward earnings (~$3.12 EPS estimate) and 17.6x forward EBITDA, significantly above the industry average of ~12x
• Options strategist recommends selling a November $85 put and $105 call for $2.25 credit, targeting 16% annualized return if stock remains stable, as implied volatility has exceeded realized volatility

AstraZeneca announced it will invest over $1 billion in Massachusetts as part of a broader $50 billion U.S. investment plan, expecting to expand its state workforce by more than 50% in the coming years. The company opened a new 570,000-square-foot R&D center in Cambridge focusing on cancer, chronic and rare diseases, and cell therapies. This move aligns with a broader trend of global drugmakers expanding their U.S. presence to strengthen supply chains and domestic capacity.

• The new 18-story facility in Kendall Square will house nearly 2,000 researchers and scientists, featuring 10 floors of laboratories equipped with robotics, automation, and AI
• AstraZeneca currently operates 24 sites across the U.S. and employs more than 25,000 people in the country, with the Cambridge site joining its other major research center in Gaithersburg, Maryland
• The investment follows a trend among major drugmakers including Pfizer, Roche, and Eli Lilly to boost U.S. manufacturing and research capabilities

Flávio Bolsonaro and incumbent Luiz Inácio Lula da Silva will face off in Brazil's presidential run-off on October 25 after neither secured a majority in the first round. Bolsonaro's better-than-expected first-round performance, beating Lula by nearly 2 percentage points, has made him the heavy favorite with betting markets now giving him over 80% odds of winning. Brazilian stocks surged on the news, with investors viewing Bolsonaro as more market-friendly due to his promises of greater fiscal discipline.

• Bolsonaro's odds of winning jumped from 60% before the first round to over 80-85% on prediction platforms after he unexpectedly beat Lula in the initial vote count by nearly 2 percentage points
• Brazilian assets rallied sharply following the result, with the iShares MSCI Brazil ETF gaining 15%, the real surging 19%, and Brazil's local stock index up 8%
• Investors favor Bolsonaro over Lula due to his fiscal discipline promises, particularly relevant as Brazil's inflation rate was nearly 10% in June

US Vice President JD Vance confirmed Monday that a long-planned Alaska LNG pipeline will move forward, though details with South Korea still need finalization. Last week, President Trump announced South Korea would invest $200 billion in US projects including this pipeline, but Seoul indicated the LNG project is not yet finalized.

• Trump announced plans for South Korea to invest $200 billion in US projects, including the Alaska LNG pipeline, but South Korea quickly suggested the deal was not set in stone
• Vance expressed confidence the project will proceed, citing strong demand for American natural gas
• Details of the partnership between the US and South Korea for the pipeline project remain under negotiation

Sainsbury's, Britain's second-largest grocer, held merger talks with smaller rival Morrisons between November 2025 and February 2026 about a potential multibillion-pound deal, but Sainsbury's walked away. The talks are no longer active, though people close to the situation have not ruled out future negotiations.

• Both Sainsbury's and Morrisons declined to comment on the reports; Morrisons is owned by US private equity firm Clayton Dubilier & Rice, which acquired it for £7 billion in 2021
• Britain's competition regulator previously blocked Sainsbury's proposed £7.3 billion takeover of Asda in 2019, suggesting regulatory scrutiny could pose challenges to any future grocery mergers
• Morrisons' owner Clayton Dubilier & Rice reportedly remains open to a tie-up with competitors, indicating continued interest in consolidation within the UK grocery sector

Roche's Genentech unit agreed to pay up to $1.27 billion to license Alector's experimental Parkinson's disease treatment AL050. The deal includes $100 million upfront and up to $1.17 billion in milestone payments tied to development, regulatory, and sales targets, plus royalties. This marks Roche's latest licensing agreement as it expands its drug pipeline.

• Genentech receives exclusive worldwide rights to develop, manufacture, and commercialize AL050, an enzyme replacement therapy targeting GCase enzyme deficiency linked to Parkinson's disease
• The deal structure includes $100 million upfront, up to $1.17 billion in milestone payments, and royalty payments to Alector
• This follows Roche's June 2026 licensing deal with Nurix Therapeutics worth up to $2.3 billion for a blood cancer drug, part of its broader pipeline expansion strategy

Microsoft CEO Satya Nadella, who successfully transformed the company into a cloud powerhouse after taking over in 2014, now faces the challenge of establishing Microsoft as a leader in the AI era. Nearly four years into the AI boom, Microsoft lacks a breakout AI product despite early investments in OpenAI, and its stock has underperformed peers in 2025. Nadella is attempting another business model shift, this time centering around token-based, consumption-based pricing rather than traditional subscriptions.

• Microsoft has 30 million Copilot seats out of 450+ million commercial Office 365 users, indicating limited AI adoption despite charging $30 per user monthly for the add-on service
• The company is pivoting from subscription pricing to usage-based billing (consumption model based on tokens), with products like GitHub Copilot showing 60% sales growth acceleration after implementing the new pricing model
• Microsoft's relationship with OpenAI has weakened - its exclusive cloud provider status ended, and its IP license became non-exclusive, while competitors like Anthropic, Google, and Nvidia gain ground in AI models and applications

Poland's antitrust regulator UOKiK has charged Google with abusing its dominant market position during negotiations with Polish media publishers over content payments. The charges relate to how Google negotiates remuneration for displaying articles and snippets in its search results, Google News, and Discover services, with the regulator alleging Google failed to provide necessary data for fair negotiations.

• UOKiK alleges Google created an information imbalance by withholding data publishers needed to properly assess payment offers, making negotiations 'illusory' and allowing Google to impose terms
• The dispute stems from a 2024 Polish law implementing an EU directive requiring online services to compensate press publishers for using their content
• Google faces a potential fine of up to 10% of its turnover if found guilty; this investigation is separate from a December 2025 EU probe into Google's use of publishers' content in AI services

Vaxcyte announced its experimental pneumococcal vaccine VAX-31 met primary endpoints in a late-stage trial for adults aged 50 and older, causing shares to jump 30%. The vaccine targets pneumococcal disease, which causes pneumonia, meningitis, and bloodstream infections particularly dangerous for older adults.

• VAX-31 produced immune responses comparable to Pfizer's Prevnar 20 and Merck's Capvaxive against 28 bacterial strains, with stronger responses against three unique strains and strain 20B
• The vaccine showed a consistent safety profile across age groups with no serious adverse events related to the vaccines
• Vaxcyte expects results from two additional late-stage trials in first half 2027 and plans to submit a US marketing application in first half 2028